Shopping Cart 0
Cart Subtotal
AED 0

Cyxone AB (CYXO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

Cyxone AB (Cyxone) is a biopharmaceutical company that develops cyclotide drugs for immune-related diseases. The company develops T20K, a compound to inhibit pro-inflammatory cytokines, such as IL2 that helps to reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. It also offers cyclotides, a new class of highly specific low toxicity drugs that can be used for several immune-related diseases and cancers. Cyxone also develops biological drugs with pharmacological effects for MS sufferers and RRMS patients. The company also conducts preclinical studies and clinical trials. It operates across Austria and Germany. Cyxone is headquartered in Malmo, Sweden.

Cyxone AB (CYXO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cyxone AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Cyxone AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Cyxone AB, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

Cyxone Acquires Rights of Rabeximod from Oxypharma 10

Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 11

Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 12

Partnerships 13

Cyxone Partners with Medical University of Vienna 13

Cyxone Enters into Agreement with University of Queensland 14

Cyxone Enters into Agreement with Sourcia 15

Cyxone Enters into Agreement with Bachem 16

Cyxone AB-Key Competitors 17

Cyxone AB-Key Employees 18

Cyxone AB-Locations And Subsidiaries 19

Head Office 19

Recent Developments 20

Financial Announcements 20

Aug 17, 2018: Cyxone's interim report for January-June 2018 20

Feb 16, 2018: Cyxone : Year-end Report 1 January to 31 December 2017 22

Oct 26, 2017: Cyxone: Interim report July 1 to September 30, 2017 23

Aug 30, 2017: Cyxone: Interim report 2017-01-01 to 2017-06-30 24

Clinical Trials 25

Nov 01, 2017: Existing Rabeximod can be used in Cyxone's planned Phase 2b study in patients with rheumatoid arthritis 25

Other Significant Developments 26

Jun 29, 2018: Cyxone appoints Mangold as market maker 26

Appendix 27

Methodology 27

About GlobalData 27

Contact Us 27

Disclaimer 27


List Of Figure

List of Figures

Cyxone AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cyxone AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Cyxone AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cyxone AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cyxone AB, Deals By Therapy Area, 2012 to YTD 2018 8

Cyxone AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Cyxone Acquires Rights of Rabeximod from Oxypharma 10

Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 11

Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 12

Cyxone Partners with Medical University of Vienna 13

Cyxone Enters into Agreement with University of Queensland 14

Cyxone Enters into Agreement with Sourcia 15

Cyxone Enters into Agreement with Bachem 16

Cyxone AB, Key Competitors 17

Cyxone AB, Key Employees 18

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Cyxone AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Cyxone AB (Cyxone) is a biopharmaceutical company that develops cyclotide drugs for immune-related diseases. The company develops T20K, a compound to inhibit pro-inflammatory cytokines, such as IL2 that helps to reduce clinical symptoms in an animal model for multiple sclerosis after oral administration. It also offers cyclotides, a new class of highly specific low toxicity drugs that can be used for several immune-related diseases and cancers. Cyxone also develops biological drugs with pharmacological effects for MS sufferers and RRMS patients. The company also conducts preclinical studies and clinical trials. It operates across Austria and Germany. Cyxone is headquartered in Malmo, Sweden.

Cyxone AB (CYXO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cyxone AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Cyxone AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Cyxone AB, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

Cyxone Acquires Rights of Rabeximod from Oxypharma 10

Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 11

Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 12

Partnerships 13

Cyxone Partners with Medical University of Vienna 13

Cyxone Enters into Agreement with University of Queensland 14

Cyxone Enters into Agreement with Sourcia 15

Cyxone Enters into Agreement with Bachem 16

Cyxone AB-Key Competitors 17

Cyxone AB-Key Employees 18

Cyxone AB-Locations And Subsidiaries 19

Head Office 19

Recent Developments 20

Financial Announcements 20

Aug 17, 2018: Cyxone's interim report for January-June 2018 20

Feb 16, 2018: Cyxone : Year-end Report 1 January to 31 December 2017 22

Oct 26, 2017: Cyxone: Interim report July 1 to September 30, 2017 23

Aug 30, 2017: Cyxone: Interim report 2017-01-01 to 2017-06-30 24

Clinical Trials 25

Nov 01, 2017: Existing Rabeximod can be used in Cyxone's planned Phase 2b study in patients with rheumatoid arthritis 25

Other Significant Developments 26

Jun 29, 2018: Cyxone appoints Mangold as market maker 26

Appendix 27

Methodology 27

About GlobalData 27

Contact Us 27

Disclaimer 27


List Of Figure

List of Figures

Cyxone AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cyxone AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Cyxone AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Cyxone AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Cyxone AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Cyxone AB, Deals By Therapy Area, 2012 to YTD 2018 8

Cyxone AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Cyxone Acquires Rights of Rabeximod from Oxypharma 10

Cyxone to Acquire T20K Patent Portfolio from Medical University of Vienna 11

Cyxone Acquires Cyclotide Patent Rights from MedUni Vienna and University Medical Center Freiburg 12

Cyxone Partners with Medical University of Vienna 13

Cyxone Enters into Agreement with University of Queensland 14

Cyxone Enters into Agreement with Sourcia 15

Cyxone Enters into Agreement with Bachem 16

Cyxone AB, Key Competitors 17

Cyxone AB, Key Employees 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Cyxone AB, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.